Introduction {#Sec1}
============

Cardiogenic shock (CS) is a fatal complication of acute myocardial infarction (AMI), occurring in 5 to 15% AMI cases \[[@CR1]--[@CR3]\]. Although CS has been declining slowly over the last decade due to the development of the therapeutic strategies \[[@CR4]\], it has remained responsible for approximate 30--50% cardiac death in the AMI patients \[[@CR5]\]. People have been making maneuvers to develop different mechanical circulatory support for improving the hemodynamic status in case of CS. To our disappointment, the efficacy in survival improvement is not significant according to the limited data \[[@CR6]--[@CR9]\]. On the contrary, a few studies suggested the intra-aortic balloon pump (IABP) could improve the prognosis in the patients without CS \[[@CR10]--[@CR12]\], which implied the mechanical circulatory support probably produce better efficacy in the patients with high likelihood of developing CS.

So far there is no definite criteria for identification of the subset patients. The previous studies have used various definitions, such as systolic blood pressure below 100 mmHg, heart rate above 100 beats per minute, Killips classification≥2, impaired left ventricular function, multivessel disease, etc \[[@CR10], [@CR12]--[@CR14]\]. These different risk factors in the definitions are acquired from empirical experiences or regression analysis, which is also the leading cause of the heterogeneous results of the previous studies. Moreover, the prognosis of the AMI patients who actually develop CS in the real world is essential for assessing the value of prophylactic utility of mechanical circulatory support. Nonetheless, the relative studies and data on this facet are considerable limited. Thus, we perform the current study to compare the clinical outcomes of different onset time of CS in the patients with ST segment elevation myocardial infarction (STEMI) and evaluate the short and long-term prognosis of developed CS.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The diagnosis of STEMI was based on the criteria of American College of Cardiology/American Heart Association (ACC/AHA) \[[@CR15]\] and the European Society of Cardiology \[[@CR16]\]. Data was obtained from the databases in our institution and the ethics has been approved by the Medical Ethics Committee of Nanjing Drum Tower Hospital, Medical School of Nanjing University (2015--059-01).

The including criteria were as follows: (1) patients aged 18 \~ 90 years; (2) all patients presented to the emergency department of our hospital for AMI; (3) STEMI diagnosed by electrocardiography (ECG) in emergency department; (4) the patients were eligible for primary percutaneous coronary intervention (pPCI) and willing to receive the procedure.

The exclusion criteria were as follows: (1) the patients were younger than 18 years or older than 90 years old; (2) the patients did not receive emergency angiography; (3) the patients did not receive emergency revascularization after angiography; (4) the patients were suitable for emergency coronary artery bypass graft surgery (CABG); (5) the patients lost follow-up.

During the period from November 2010 to December 2017, total of 950 patients were diagnosed STEMI. The enrollment and exclusion procedure were shown in the flow chart (Fig. [1](#Fig1){ref-type="fig"}). Finally, 675 patients were enrolled in the study analysis. The patient cohort was divided into 3 groups based on the hemodynamic status and CS onset stage: 562 patients without CS during hospitalization (Non-CS group), 32 patients presenting CS when admitted in emergency department (CS on admission group) and 81 patients without CS on admission but developed CS during pPCI or after pPCI (Developed CS group). Fig. 1Flowchart of patient inclusion. STEMI: ST-segment elevation myocardial infarction; CS: cardiogenic shock; CABG: coronary artery bypass graft surgery

Study protocol {#Sec4}
--------------

All the patients with acute chest pain in the emergency room accepted ECG within 10 min. STEMI was defined as new onset of ST segment elevation at the J point in at least 2 contiguous leads of above 2 mm in men or above 1.5 mm in women at V2 and V3 lead and/or of above 1 mm in other leads. The new onset left bundle branch block was regarded equivalent to STEMI \[[@CR17]\]. After taking loading dose of dual antiplatelet drugs (aspirin 300 mg and ticagrelor 180 mg/clopidogrel 600 mg), patients were immediately transferred to the catheterization laboratory (Cath Lab) for emergency coronary angiography. Heparin was administered at a dose of 70--100 IU/kg, while tirofiban, urokinase or argatroban were used if necessary. Revascularization strategy was individualized according to the angiography results. CS was defined as systolic blood pressure \< 90 mmHg for \> 30 min, the need for infusion of inotropic agents to maintain adequate blood pressure or clinical signs of pulmonary congestion and end-organ hypoperfusion. If the STEMI patients were likely to develop CS during pPCI, whether the prophylactic IABP was deployed depended on the judgment of the interventionists. If the patients had already experienced hemodynamic instability or CS after admission, the rescue IABP and/or vasoactive agents were administrated also at the discretion of the interventionists. All the procedures were accomplished by experienced and qualified interventionists.

Follow up {#Sec5}
---------

The patients were followed up via telephone or clinics. The follow-up was carried out periodically until date of death, or 30 October 2018. Endpoints include all cause death and major adverse cardiac events (MACE) at 30 days, 12 months and 80 months. MACE was defined as composite of cardiac death, recurrent myocardial infarction (MI) or angina, non-fatal stroke and the re-hospitalization due to worsening of cardiac function. The cardiac death was defined as the deaths due to cardiac diseases such as myocardial infarction, arrhythmia, heart failure and any death that was not clearly non-cardiac.

Statistical analysis {#Sec6}
--------------------

The continuous variables were described as the mean ± standard deviations (SD) when they were normally distributed or median and interquartile range (IQR) when they were skewed. The categorical variables were presented as frequency and percentages. The comparisons of continuous variables among the three groups were used by one-way ANOVA or Kruskal-Wallis test. The comparisons of categorical variables among the groups are used by χ^2^ test or Fisher test. Survival analysis and cumulative incidence of MACE was assessed by Kaplan-Meier plot and Log rank test. Univariate and multivariate COX proportional hazard model are established for identification of the independent predictors. *P* value \< 0.05 is considered as statistical significance and intervals (CI) of 95% is applied in the overall cohort. The statistical analysis was performed by SPSS 17.0 (SPSS Inc., Chicago, Ill., USA) and STATA 12.0 (StataCop., College Station, Texas, USA).

Result {#Sec7}
======

Characteristics of study cohort {#Sec8}
-------------------------------

Total 675 patients were enrolled in this study cohort. The mean age of the patients was 64 ± 13 years and 79% were male. Based on the different onset stage of CS, 32 patients (5.6%) presented CS on admission and 81 patients (14.1%) developed CS later during hospitalization (in Cath Lab or CCU). The rest patients had no CS (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of the study cohortNon-CS (*n* = 562)CS on admission (*n* = 32)Developed CS (*n* = 81)*p-*valueAge (years), mean ± SD64 ± 12.766 ± 11.764 ± 12.70.593Male sex, n (%)444 (79)25 (78)64 (79)0.993Hypertension, n (%)359 (64)16 (50)44 (54)0.089Diabetes, n (%)142 (25)14 (44)13 (16)0.009^\#,\ &&^Smoking, n (%)315 (56)17 (53)46 (57)0.938Prior stroke, n (%)76 (14)7 (22)10 (12)0.383Hyperlipidaemia, n (%)44 (8)5 (16)5 (6)0.233Multivessel lesions, n (%)140 (25)13 (41)32 (40)0.005^\#,\ \*\*^Known kidney dysfunction, n (%)67 (12)8 (25)12 (15)0.086Prior MI, n (%)15 (3)3 (9)2 (2)0.09Pre-procedural SBP (mmHg), mean ± SD125 ± 18.980 ± 6.6112 ± 20.6\< 0.001^\#\#\#,\ \*\*\*,\ &&&^Pre-procedural HR (bpm), mean ± SD79 ± 14.7114 ± 18.587 ± 16.5\< 0.001^\#\#\#,\ \*\*\*,\ &&&^Shock index, mean ± SD0.65 ± 0.160.96 ± 0.220.81 ± 0.25\< 0.001^\#\#\#,\ \*\*\*,\ &&&^LVEF(%), mean ± SD45 ± 5.644.6.445 ± 6.60.319Creatinine (mmol/L), mean ± SD70(24)76 (39)71 (24)0.409TG (mmol/L), mean ± SD1.66 ± 1.091.39 + ±0.731.61 ± 0.880.377TCh (mmol/L), mean ± SD4.29 ± 1.024.27 ± 1.194.27 ± 0.970.985LDL-C (mmol/L), mean ± SD2.38 ± 0.742.46 ± 0.842.41 ± 0.700.792HDL-C (mmol/L), mean ± SD1.00 ± 0.381.00 ± 0.280.95 ± 0.340.525Symptom-wire interval (min),median (IQR)240 (328)168(202)237 (242)0.067IABP utility, n (%)15 (3)8 (25)21 (26)\< 0.001^\#\#\#,\ \*\*\*^Anterior MI, n (%)275 (49)10 (31)29 (36)0.018^\#,\*^Killips classification\< 0.001^\#\#\#,\*,&&&^ I, n (%)463 (82)062 (77) II, n (%)88 (16)013 (16) III, n (%)12 (2)06 (7) V, n (%)032 (100)0Post-procedure TIMI flow0.079 3, n (%)557 (99)31 (97)78 (96) 2, n (%)4 (1)0 (0)3 (4) 1, n (%)1 (0)1 (3)0 (0)IRA\< 0.001^\#\#,\ \*^ LM/LM-LAD, n (%)286 (51)10 (31)29 (36) LCX/OM, n (%)90 (16)2 (6)11 (13) RCA/PDA/PL, n (%)186 (33)20 (63)41 (51)Medicine β blocker, n (%)483 (86)21 (67)63 (78)0.177 ACEI/ARB, n (%)427 (76)21 (67)54 (67)0.517 Aldactone, n (%)90 (16)11 (33)15 (18)0.427*SBP* Stytolic blood pressure, *HR* Heart rate, *bpm* beats per minute, *SI* Shock index, *LVEF* Left ventricular ejection fraction, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *TCh* Total cholesterol, *IABP* Intra-aortic balloon pump;MI: myocardial infarction, *TIMI* Thrombolysis in myocardial infarction, *IRA* Infarct-related artery, *LM* Left main artery, *LAD* Left anterior descending branch, *LCX* Left circumflex branch, *OM* Obtuse marginal branch, *RCA* Right coronary artery, *PDA* Posterior descending artery, *PL* Posterior branch of left ventricle, *ACEI* Angitensin conveting enzyme inhibitor, *ARB* Angiotensin receptor blocker\# *P* \< 0.05, \#\#*P* \< 0.01, \#\#\# *P* \< 0.001: Non-CS group vs CS on admission group\* *P* \< 0.05,\*\**P* \< 0.01,\*\*\* *P* \< 0.001: Non-CS group vs Developed CS group& *P* \< 0.05,&&*P* \< 0.01, &&& *P* \< 0.001: CS on admission group vs Developed CS group

CS on admission group had higher percentage of diabetes than Non-CS group and Developed CS group (*P* = 0.021 and *P* = 0.002, respectively). The pre-procedural systolic blood pressure (SBP) and pre-procedural heart rate (HR) in CS on admission group were both significantly different from the other two groups (*P* \< 0.001 for both). Correspondingly, the shock index (SI) in the CS on admission group was therefore the highest. There were more patients had left main artery (LM)/ left anterior descending branch (LAD) as culprit in Non-CS group whereas more patients had right coronary artery (RCA) as culprit in CS on admission group (*P* \< 0.001). The patients in Developed CS group had higher proportion of Killips II/III than the patients in Non-CS group (Table [1](#Tab1){ref-type="table"}).

Endpoints follow-up {#Sec9}
-------------------

The patient cohort were followed up for median 36 months (IQR: 23 \~ 59 months). There were total 78 patients (11.6%) experiencing death of different causes. Among them, 18 patients died from non-cardiac origins diseases (multi-organs failure: 8 patients, tumor: 5 patients, infection of lungs: 2 patients, end stage of renal dysfunction: 1 patient, trauma: 2 patients).

The all cause death and MACE at 30 days were shown in the Table [2](#Tab2){ref-type="table"}. There was only higher incidence of non-fatal stroke in the CS on admission group in spite of the quite small frequency. The other endpoints were similar among the three groups. Table 2Endpoint events in the study cohort at 30 daysEventsNon-CS (***n*** = 562)CS on admission (***n*** = 32)Developed CS (***n*** = 81)***p-***valueAll cause death, n (%)13(2)1(3)2(2)0.956MACE Cardiac death, n (%)13(2)1(3)2(2)0.956 Angina/Recurrent MI, n (%)4(1)0(0)0(0)0.667 Worsening of cardiac function, n (%)2(0)1(3)1(1)0.101 Non-fatal stroke, n (%)0(0)1(3)0(0)*P* \< 0.001*MI* Myocardial infarction, *MACE* Major adverse cardiac events

The middle-term outcomes were exhibited in Fig. [2](#Fig2){ref-type="fig"}. At 12 months, the curve of all cause death and cardiac death did not separate (Fig. [2](#Fig2){ref-type="fig"}a and b). However, the incidence of MACE in CS on admission group had already been significantly higher than the other groups (Fig. [2](#Fig2){ref-type="fig"}c). With regard to the long-term outcomes, the CS on admission group had the lowest survival rate among the three groups whereas Develop CS group had lower survival rate than Non-CS group numerically with a trend towards statistical significance (Fig. [3](#Fig3){ref-type="fig"}a). Furthermore, the incidence of cardiac death in the Non-CS group was the lowest, while the cardiac death rate was not different between CS on admission group and Developed CS group (Fig. [3](#Fig3){ref-type="fig"}b). The incidence of MACE in the CS on admission group was much higher compared with the other two groups. But the MACE in the Non-CS group and Developed CS group were not significantly different (Fig. [3](#Fig3){ref-type="fig"}c). Fig. 2The outcomes of the study cohort at 12 months. **a**. survival curves. **b**. cardiac death curves. **c**. MACE curves. The incidence of MACE at 12 months in the CS on admission group was significantly higher than the other two groups. On the contrary, there were no differences in the all cause death and cardiac death at 12 months among the three groups MACE: major adverse cardiac eventsFig. 3The long-term outcomes of the study cohort. **a**. survival curves. **b**. cardiac death curves. **c**. MACE curves. We found the CS on admission group had much lower survival rate and higher incidence of cardiac death and MACE than the other two groups. CS: cardiogenic shock; MACE: major adverse cardiac events

COX proportional hazard models were established for all cause death, cardiac death and MACE to adjust the confounding factors and identify the independent predictors of the long-term outcomes. There were total 24 variables participating the univariate analysis including 10 continuous variables and 14 categorical variables. After univariate analysis, the covariates with *P* \< 0.1 and the covariates with *P* \> 0.1 but with clinical significance were extracted for multivariate regression analysis. The variables were selected with likelihood ratio test and the covariates with *P* \< 0.05 were considered statistically significant.

After univariate and multivariate analysis, there were four covariates as independent predictors of all cause death: age, male sex, prior stroke and left ventricular ejection fraction (LVEF) (Table [3](#Tab3){ref-type="table"}). As to the cardiac death, the following covariates were identified as independent predictors: age, male sex, prior stroke, LVEF, CS on admission and developed CS (Table [4](#Tab4){ref-type="table"}). With regard to the MACE, six covariates were identified as independent predictors: age, prior stroke, LVEF, multivessel lesions, post-PCI TIMI grade 1 and CS on admission (Table [5](#Tab5){ref-type="table"}). Table 3COX proportional hazard model for the all cause death of the study cohortUnivariateMultivariableHR95% CI*p*-valueHR95% CI*p*-valueAge1.0941.070--1.119\< 0.0011.0711.045--1.099\< 0.001Male sex3.3832.167--5.282\< 0.0012.1051.292--3.4310.003Hypertension1.130.709--1.8020.608------Diabetes1.1930.733--1.9410.478------Smoking0.7530.353--1.1650.135------Prior Stroke3.7492.348--5.985\< 0.0012.2091.347--3.6210.002Hyperlipdemia0.2790.069--1.1370.075------Known kidney dysfunction1.6631.042--2.6520.033------Prior MI2.1380.780--5.8650.14------Pre-procedural SBP0.9880.977--0.9980.023------Pre-procedural HR1.0211.009--1.0330.001------LVEF, per % increased0.90.868--0.933\< 0.0010.9310.893--0.967\< 0.001TG, per mmol/L increased0.720.565--1.0030.056------TCh, per mmol/L increased0.9650.769--1.2090.755------LDL-C, per mmol/L increased0.8720.634--1.1990.4------HDL-C, per mmol/L increased1.610.712--2.5530.079------Multivessel lesions1.7781.148--2.7540.01------Time of symptom-wire, per hour increased1.0161.008--1.024\< 0.001------IABP utility1.4490.697--3.0140.32------Shock index (per 0.1 increased)1.1521.078--1.230\< 0.001------Anterior MI0.7260.465--1.1320.158------Onset stage of CS Non- CS (reference)1---------- CS on admission3.4121.619--7.1910.001------ developed CS1.6920.954--2.9990.072------Killips Classification Killips = 1(reference)1---------- Killips = 22.4051.426--4.0550.001------ Killips = 33.7741.493--9.5380.005------ Killips = 44.5662.131--7.782\< 0.001------post-PCI TIMI flow of IRA 3(reference)1---------- 21.6510.229--11.8980.619------ 14.7620.658--34.4650.122------*CS* Cardiogenic shock, *SBP* Stytolic blood pressure, *HR* Heart rate, *bpm* beats per minute, *LVEF* Left ventricular ejection fraction, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *TC* Total cholesterol, *IABP* Intra-aortic balloon pump, *MI* Myocardial infarction, *TIMI* Thrombolysis in myocardial infarction, *IRA* Infarct-related artery, *PCI* percutaneous coronary interventionTable 4COX proportional hazard model for the cardiac death of the study cohortUnivariateMultivariateHR95% CI*p*-valueHR95% CI*p*-valueAge1.0661.041--1.091\< 0.0011.0681.038--1.099\< 0.001Male sex3.5432.132--5.889\< 0.0012.1001.196--3.6880.01Hypertension1.9681.082--3.5820.027------Diabetes1.4290.835--2.4440.193------Smoking0.6840.288--1.0110.099------Prior Stroke1.8651.007--3.4530.0471.9891.124--3.5230.018Hyperlipdemia0.1770.024--1.2760.086------Known kidney dysfunction1.7641.035--3.0070.037------Prior MI1.3450.328--5.5190.681------Pre-procedural SBP0.9920.975--1.0010.081------Pre-procedural HR1.0191.003--1.0350.017------LVEF, per % increased0.9490.909--0.9910.0170.9110.871--0.954\< 0.001TG, per mmol/L increased0.8890.679--1.1650.394------TCh, per mmol/L increased0.8110.623--1.0550.118------LDL-C, per mmol/L increased0.740.518--1.0570.098HDL-C, per mmol/L increased1.0750.572--2.0200.823------Multivessel lesions1.9541.191--3.2080.008------Time of symptom-wire, per hour increased1.0110.999--1.0230.081------IABP utility2.0040.951--4.2240.068------Shock index (per 0.1 increased)1.21.079--1.3340.001------Anterior MI0.7950.479--1.3190.374------Onset stage of CS Non- CS (reference)1----1---- CS on admission3.3451.496--7.4790.0032.7391.210--6.2040.016 developed CS2.3461.252--4.3950.0082.2331.164--4.2860.016Killips Classification Killips = 1(reference)1---------- Killips = 22.7371.502--4.9880.001------ Killips = 33.841.694--8.7000.007------ Killips = 44.131.460--11.6810.001------post-PCI TIMI flow of IRA 3(reference)1---------- 24.4031.071--18.0980.04------ 16.4881.191--27.2280.035------*MACE* Major adverse cardiac events, *CS* Cardiogenic shock, *SBP* Stytolic blood pressure, *HR* Heart rate, *bpm* beats per minute, *LVEF* Left ventricular ejection fraction, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *TC* Total cholesterol, *IABP* Intra-aortic balloon pump, *MI* Myocardial infarction, *TIMI* Thrombolysis in myocardial infarction, *IRA* Infarct-related artery, *PCI* Percutaneous coronary interventionTable 5COX proportional hazard model for the MACE of the study cohortUnivariateMultivariateHR95% CI*p*-valueHR95% CI*p*-valueAge1.0281.016--1.040\< 0.0011.0171.005--1.0310.005Male sex1.4131.010--1.8820.043------Hypertension1.0090.760--1.3400.95------Diabetes1.230.912--1.6600.175------Smoking0.8120.617--1.0680.136------Prior Stroke1.8631.338--2.594\< 0.0011.6391.146--2.3440.007Hyperlipdemia0.9090.545--1.5140.713------Known kidney dysfunction0.8270.589--1.1620.274------Prior MI1.5490.763--3.1450.226------Pre-procedural SBP0.9960.990--1.0020.213------Pre-procedural HR1.0050.997--1.0130.192------LVEF, per % increased0.9620.940--0.9840.0010.9780.954--0.9970.044TG, per mmol/L increased0.8920.770--1.0320.124------TCh, per mmol/L increased0.9270.807--1.0650.285------LDL-C, per mmol/L increased0.9890.933--1.0480.700------HDL-C, per mmol/L increased0.8270.556--1.2300.348------Multivessel lesions1.4441.091--1.9110.011.4621.098--1.9470.009Time of symptom-wire, per hour increased1.0030.994--1.0130.477------IABP utility1.1080.665--1.8470.693------Shock index (per 0.1 increased)1.0511.003--1.1020.038------Anterior MI0.7390.562--0.9720.031------Onset stage of CS Non- CS (reference)1----1---- CS on admission2.2521.345--3.7700.0021.9481.164--3.2610.011 developed CS1.0690.711--1.6080.7481.0820.691--1.6910.73Killips Classification Killips = 1(reference)1---------- Killips = 21.340.933--1.9250.113------ Killips = 31.8640.914--3.8010.087------ Killips = 42.3891.423--4.0130.001------post-PCI TIMI flow of IRA 3 (reference)1----1---- 22.5280.938--6.8120.0672.6040.634--10.0780.181 13.380.837--13.6430.0873.1081.130--8.0260.02*MACE* Major adverse cardiac events, *CS* Cardiogenic shock, *SBP* Stytolic blood pressure, *HR* Heart rate, *bpm* beats per minute, *LVEF* Left ventricular ejection fraction, *TG* Triglyceride, *LDL-C* Low density lipoprotein cholesterol, *HDL-C* High density lipoprotein cholesterol, *TC* Total cholesterol, *IABP* Intra-aortic balloon pump, *MI* Myocardial infarction, *TIMI* Thrombolysis in myocardial infarction, *IRA* Infarct-related artery, *PCI* Percutaneous coronary intervention

Discussion {#Sec10}
==========

The incidence of CS secondary to STEMI varies from 4.0 to 6.2% in Chinese patients cohort \[[@CR18], [@CR19]\], which is quite similar to the western countries \[[@CR2], [@CR20]\]. It has been reported that time of revascularization is a predictor of the survival at 1 year \[[@CR21]\]. Nonetheless, the mortality of CS is still up to 50% so far according to the previous data \[[@CR5], [@CR22]--[@CR24]\], although the timely reperfusion has been extensively performed worldwide for decades.

Total 113 patients in our study cohort presented CS after STEMI occurrence, accounting for around 16.7%. Thirty-two patients of them had been in CS status when admission while the other 81 patients developed CS during pPCI or after pPCI, which was quite similar to the previous findings \[[@CR25], [@CR26]\]. Hence, it is necessary to pay more attention to the likelihood of progressive or sudden exacerbation of hemodynamical status. One of the most important cause responsible for CS developed during hospitalization is reperfusion injury (RI) as it is associated with approximate 50% of the infarct size \[[@CR27]\]. That could explain that most of the patients with developed CS present hemodynamical compromising after restoration of coronary blood flow in the real world. Some factors were identified as predictors of developed CS, including age, SBP, HR, SI, diabetes, LVEF, Killips classification, etc \[[@CR26], [@CR28], [@CR29]\]. However, there were few studies evaluating the impact of the different onset stage of CS on the long-term prognosis.

In the current study, we found the incidence of all cause death, cardiac death and MACE at 30 days were all similar among the three groups. On the contrary, Laust Obling et al. revealed the CS patients had significant lower survival rate than non-CS patients at 30 days, while the patients with different time onset of CS had similar survival rate \[[@CR28]\]. The constitution of infarct location is probably the pivotal factor which makes the significant difference. In the Obling's study, anterior AMI accounted for 65% in the late CS group and 43% in CS on admission group. In contrast, anterior AMI only accounted for 31% in the CS on admission group and 35% in Developed CS group in our cohort, while inferior/posterior AMI totally accounted for nearly 55% in CS-containing groups (CS on admission +Developed CS). Thus, the current cohort had much better short-term prognosis than Obling's study cohort. Moreover, LM occlusion mostly manifested widely depressed ST segment on ECG, which were not included in our study cohort. The short-term mortality of the current cohort was thereby much lower.

With regard to the long-term outcomes, patients in the CS on admission group had the worst prognosis no matter in all cause death, cardiac death or MACE, whereas the patients in Non-CS group had the best results in contrast. Of note, the Developed CS group had a higher survival rate than CS on admission group and had a trend towards a lower survival rate than the Non-CS group. Similarly, the incidence of cardiac death and MACE in the Developed CS group also laid between the other two groups. A previous study has reported that some predictors including age, estimated glomerular filtrated rate, LVEF, SI were related to the 5-year MACE in AMI patients \[[@CR30]\]. In the current cohort, the influences of the different onset stage of CS on the long-term outcomes were the main concerns. Thus, we introduced this variable into the multivariate model. After adjustment of the confounding factors, the different onset stage of CS was not an independent predictor of long-term all cause death. As to all cause death, there was also death of other origins including multi-organs failure, cancer, pulmonary disease, which were more associated with the basic conditions of the patients rather than shock. Nevertheless, CS on admission and developed CS were both independent predictors of cardiac death, while only CS on admission was the independent predictor of MACE. It is interesting that developed CS could cause higher cumulative incidence of cardiac death in comparison with Non-CS group, whereas the MACE was similar between the two groups. It was thought partly associated with the different constitution between the two groups. Developed CS group had higher proportion of inferior/posterior infarction and lower proportion of anterior infarction than Non-CS group. Anterior infarction is more likely to cause left ventricular remodeling and recurrent heart failure during the long-term follow-up.

Our findings had indicated that the onset stage of CS had an impact on the long-term prognosis. A study performed by Giuseppe et al. revealed that the mortality in the patients with developed CS was numerically higher than the patients with CS on admission but without statistical significance \[[@CR26]\]. In that study, they just focused on the in-hospitalization death, not reporting the long-term death. Besides, the cohort in his study also included the patients without revascularization, which was quite different from our patient cohort. Another study carried out by Lindholm et al. demonstrated that the different onset time of CS after AMI occurrence could produce significantly different outcomes \[[@CR31]\]. Early CS showed better prognosis than late CS no matter in short-term and long-term mortality, which seemed to be opposite to the current study. However, it should be noticed that the group division criteria were set different from our study. Moreover, the patient cohort in Lindholm's study enrolled both STEMI and non-ST segment elevation myocardial infarction (NSTEMI). NSTEMI usually causes late developed CS and leads to much higher mortality \[[@CR32]--[@CR34]\], which was probably another cause responsible for the different outcomes between the two studies.

In our study, the results coming from the real data illustrated two clinical impacts. First, CS due to STEMI definitely produces compromising long-term outcomes. The revascularization therapy should be carried out as early as possible. Second, it is important and necessary to prevent the developed CS in the patients with STEMI. The interventionists have been made lots of maneuver to figure out the strategies for preventing the developed CS, particularly due to the reperfusion injury. Mechanical circulatory supports are usually the preferable choice for this purpose. The useful predictors of developed CS has been established in lots of previous studies \[[@CR28], [@CR29], [@CR32]\]. However, it is a practical task that how to distinguish the patients with impending CS using the various predictors. There has been only a handful of studies providing the criteria for high-risk patients \[[@CR10], [@CR13], [@CR35]\]. Nonetheless, the definitions were not consistent with each other. Furthermore, the conclusions of the benefits from prophylactic use of mechanical circulatory support in the AMI patients with high risk of CS were largely acquired from observational or retrospective studies. Thus, more randomized, controlled, prospective clinical trials are necessary to confirm the value of prevention of the developed CS in STEMI patients.

Limitations {#Sec11}
===========

The current study has several limitations. (1) It is an observational study, which has the intrinsic shortcomings. The biases are unable to be avoided completely despite of the adjustment of confounding factors using regression analysis. (2) The CS caused by LM occlusion usually presents non-ST segment elevation and was not included in the current study. Consequently, the mortality of the patients presenting CS on admission was probably underestimated. (3) There were considerable STEMI patients were excluded from the current cohort due to accepting elective PCI, which accounted for approximate 19% of the total STEMI patients. It could possibly influence the assessment of the outcomes of the STEMI patients in the real world.

ACEI

:   Angiotensin converting enzyme inhibitor

AMI

:   Acute myocardial infarction

ARB

:   Angiotensin receptor blocker

CABG

:   Coronary artery bypass graft

CCU

:   Cardiac care unit

CS

:   Cardiogenic shock

HDL-C

:   High density lipoprotein cholesterol

HR

:   Heart rate

IABP

:   Intra-aortic balloon pump

IRA

:   Infarct-related artery

LAD

:   Left anterior descending branch

LCX

:   Left circumflex branch

LDL-C

:   Low density lipoprotein cholesterol

LM

:   Left main artery

LVEF

:   Left ventricular ejection fraction

MACE

:   Major adverse cardiac events

NSTEMI

:   Non-ST segment elevation myocardial infarction

OM

:   Obtuse marginal branch

PDA

:   Posterior descending artery

PL

:   Posterior branch of left ventricle

pPCI

:   Primary percutaneous coronary intervention

RCA

:   Right coronary artery

RI

:   Reperfusion injury

SBP

:   Systolic blood pressure

SI

:   Shock index

STEMI

:   ST segment elevation myocardial infarction

TCh

:   Total cholesterol

TG

:   Triglyceride

TIMI

:   Thrombolysis in myocardial infarction
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